Lifeward Ltd. files Form D for $11.16 million offering under Rule 506(b)

Lifeward Ltd. filed a Form D notice of exempt offering with the SEC, reporting a first sale date of July 6, 2026, and signing the filing on July 8, 2026. The filing is marked as a new notice with a date of first sale of 2026-07-06.¹

The issuer is identified with prior names Argo Medical Technologies Ltd. and ReWalk Robotics Ltd. Lifeward Ltd. is listed under CIK number 0001607962, with previous names Argo Medical Technologies Ltd. and ReWalk Robotics Ltd.¹ The company is organized as a company limited by shares under Israeli jurisdiction, incorporated over five years ago.¹ Its principal place of business is listed at 2 Cabot Road, Hudson, Massachusetts, 01749.¹

The filing classifies the issuer's industry as biotechnology.¹ William Mark Grant of 2 Cabot Road, Hudson, Massachusetts, is named as a related person holding the roles of executive officer and director.¹ In the signature block, however, the same individual's name appears as "Willliam Mark Grant," with three L's, differing from the spelling used in the related-persons section. The notice was signed by Willliam Mark Grant, President and CEO of the Issuer, on 2026-07-08.¹

The offering claims exemption under Rule 506(b).¹ The securities types offered include equity, debt, and options, warrants or other rights to acquire securities, along with securities to be acquired upon exercise of such rights.¹ The filing states the offering is not being made in connection with a business combination transaction.¹

On offering size, the total offering amount is listed as indefinite, with a total amount sold of $11,160,000 and remaining amount to be sold also listed as indefinite.¹ The filing reports a total of five investors who have already invested in the offering.¹ No sales commissions or finders' fees were reported, both listed at $0.¹